# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Introducing 'Zero Calcium' Categorization And Numerical Coronary Artery Calcium Score, Marking The Second FDA Clearanc...
- SEC Filing
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities available to p...
Cantor Fitzgerald analyst Ross Osborn reiterates Nano X Imaging (NASDAQ:NNOX) with a Overweight and maintains $17 price target.
Cantor Fitzgerald analyst Ross Osborn maintains Nano X Imaging (NASDAQ:NNOX) with a Overweight and lowers the price target f...
Cantor Fitzgerald analyst Ross Osborn reiterates Nano X Imaging (NASDAQ:NNOX) with a Overweight and maintains $18 price target.